These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

844 related items for PubMed ID: 33971856

  • 1. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC, Chipps B, Munoz X, Devouassoux G, Bergna M, Smith SG, Price RG, Galkin DV, Azmi J, Mouneimne D, Albers FC, Chapman KR.
    Respir Res; 2021 May 10; 22(1):144. PubMed ID: 33971856
    [Abstract] [Full Text] [Related]

  • 2. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR, Albers FC, Chipps B, Muñoz X, Devouassoux G, Bergna M, Galkin D, Azmi J, Mouneimne D, Price RG, Liu MC.
    Allergy; 2019 Sep 10; 74(9):1716-1726. PubMed ID: 31049972
    [Abstract] [Full Text] [Related]

  • 3. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE, Pelaia C, D'Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Quarato CMI, Foschino Barbaro MP.
    Ther Adv Respir Dis; 2020 Sep 10; 14():1753466620929231. PubMed ID: 32482128
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, Ortega H.
    Allergy; 2016 Sep 10; 71(9):1335-44. PubMed ID: 27087007
    [Abstract] [Full Text] [Related]

  • 6. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
    Lemiere C, Taillé C, Lee JK, Smith SG, Mallett S, Albers FC, Bradford ES, Yancey SW, Liu MC.
    Respir Res; 2021 Jun 22; 22(1):184. PubMed ID: 34158028
    [Abstract] [Full Text] [Related]

  • 7. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA.
    Albers FC, Papi A, Taillé C, Bratton DJ, Bradford ES, Yancey SW, Kwon N.
    Respir Res; 2019 Jul 30; 20(1):169. PubMed ID: 31362741
    [Abstract] [Full Text] [Related]

  • 8. Mepolizumab treatment in patients with severe eosinophilic asthma.
    Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P, MENSA Investigators.
    N Engl J Med; 2014 Sep 25; 371(13):1198-207. PubMed ID: 25199059
    [Abstract] [Full Text] [Related]

  • 9. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
    Canonica GW, Harrison TW, Chanez P, Menzella F, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, Garcia Gil E.
    Allergy; 2022 Jan 25; 77(1):150-161. PubMed ID: 33978983
    [Abstract] [Full Text] [Related]

  • 10. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience.
    Lim YT, Williams TC, Langley RJ, Weir E.
    J Asthma; 2024 Aug 25; 61(8):793-800. PubMed ID: 38240489
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG, ANDHI study investigators.
    Lancet Respir Med; 2021 Mar 25; 9(3):260-274. PubMed ID: 33357499
    [Abstract] [Full Text] [Related]

  • 14. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID.
    Lancet Respir Med; 2016 Jul 25; 4(7):549-556. PubMed ID: 27177493
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T, Odajima H, Okamasa A, Kawase M, Komatsubara M, Mayer B, Yancey S, Ortega H.
    Allergol Int; 2017 Jul 25; 66(3):445-451. PubMed ID: 28110896
    [Abstract] [Full Text] [Related]

  • 16. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.
    Carpagnano GE, Resta E, Povero M, Pelaia C, D'Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Barbaro MPF.
    Sci Rep; 2021 Mar 09; 11(1):5453. PubMed ID: 33750842
    [Abstract] [Full Text] [Related]

  • 17. Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
    Nopsopon T, Barrett NA, Phipatanakul W, Laidlaw TM, Weiss ST, Akenroye A.
    Allergy; 2024 May 09; 79(5):1195-1207. PubMed ID: 38164813
    [Abstract] [Full Text] [Related]

  • 18. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I, Stevenson M, Cooper K, Harnan S, Hamilton J, Clowes M, Carroll C, Harrison T, Saha S.
    Pharmacoeconomics; 2018 Feb 09; 36(2):131-144. PubMed ID: 28933002
    [Abstract] [Full Text] [Related]

  • 19. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
    Gibson PG, Prazma CM, Chupp GL, Bradford ES, Forshag M, Mallett SA, Yancey SW, Smith SG, Bel EH.
    Respir Res; 2021 Jun 07; 22(1):171. PubMed ID: 34098955
    [Abstract] [Full Text] [Related]

  • 20. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
    Weir E, Paton J.
    J Asthma; 2020 May 07; 57(5):521-524. PubMed ID: 30795693
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.